Abstract
Congenital chylothorax (CC) can result from a congenital malformation or an acquired obstruction or disruption of the thoracic duct. Recently, oral administration of the phosphodiesterase-5 inhibitor, sildenafil, was reported to be effective in resolving non-pulmonary lymphatic malformations in infants and young children. We report a case of CC in a late preterm infant with congenital pulmonary lymphangiectasia where octreotide was not effective, but management with oral sildenafil was successful.
MeSH terms
-
Chylothorax / congenital*
-
Chylothorax / drug therapy
-
Female
-
Humans
-
Infant, Newborn
-
Infant, Premature, Diseases / drug therapy
-
Lung / diagnostic imaging
-
Lung Diseases / congenital*
-
Lung Diseases / diagnosis
-
Lung Diseases / drug therapy
-
Lymphangiectasis / congenital*
-
Lymphangiectasis / diagnosis
-
Lymphangiectasis / drug therapy
-
Phosphodiesterase 5 Inhibitors / administration & dosage*
-
Sildenafil Citrate / administration & dosage*
-
Tomography, X-Ray Computed
Substances
-
Phosphodiesterase 5 Inhibitors
-
Sildenafil Citrate
Supplementary concepts
-
Chylothorax, congenital
-
Lymphangiectasia, pulmonary, congenital